In clinical trials, the treatment of diabetic patients with GLP-1 RA also leads to reduced pro-inflammatory activation of macrophages and favorable changes in the serum cytokines profile (decrease of TNFα, IL-1β, and IL-6 and increase of adiponectin level) [141]. Here, TNF is linked to rheumatoid arthritis.